Goldman Sachs Group Inc. Trims Stake in Korro Bio, Inc. $KRRO

Goldman Sachs Group Inc. reduced its holdings in Korro Bio, Inc. (NASDAQ:KRRO) by 10.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,944 shares of the company’s stock after selling 2,357 shares during the period. Goldman Sachs Group Inc.’s holdings in Korro Bio were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP acquired a new stake in shares of Korro Bio during the first quarter worth about $35,000. Deutsche Bank AG lifted its holdings in Korro Bio by 29.4% in the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock worth $156,000 after purchasing an additional 935 shares during the period. AlphaQuest LLC increased its holdings in shares of Korro Bio by 320.1% in the 1st quarter. AlphaQuest LLC now owns 9,196 shares of the company’s stock valued at $160,000 after purchasing an additional 7,007 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Korro Bio by 128,950.0% during the first quarter. GAMMA Investing LLC now owns 10,324 shares of the company’s stock worth $180,000 after buying an additional 10,316 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Korro Bio during the first quarter worth $185,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Stock Up 6.6%

Shares of NASDAQ:KRRO opened at $40.66 on Friday. Korro Bio, Inc. has a 52 week low of $10.29 and a 52 week high of $98.00. The company has a market cap of $381.84 million, a P/E ratio of -4.17 and a beta of 2.66. The business has a fifty day simple moving average of $23.60 and a 200-day simple moving average of $18.11.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $0.41 million. Sell-side analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on KRRO shares. Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of Korro Bio in a report on Wednesday, August 13th. Raymond James Financial decreased their price objective on shares of Korro Bio from $153.00 to $147.00 and set a “strong-buy” rating for the company in a report on Wednesday, August 13th. Finally, HC Wainwright decreased their target price on shares of Korro Bio from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $86.83.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).